Research Article
Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants

https://doi.org/10.1016/j.jbc.2021.101208Get rights and content
Under a Creative Commons license
open access

Emergence of new severe acute respiratory syndrome coronavirus 2 variants has raised concerns related to the effectiveness of vaccines and antibody therapeutics developed against the unmutated wildtype virus. Here, we examined the effect of the 12 most commonly occurring mutations in the receptor-binding domain of the spike protein on its expression, stability, activity, and antibody escape potential. Stability was measured using thermal denaturation, and the activity and antibody escape potential were measured using isothermal titration calorimetry in terms of binding to the human angiotensin-converting enzyme 2 and to neutralizing human antibody CC12.1, respectively. Our results show that mutants differ in their expression levels. Of the eight best-expressed mutants, two (N501Y and K417T/E484K/N501Y) showed stronger affinity to angiotensin-converting enzyme 2 compared with the wildtype, whereas four (Y453F, S477N, T478I, and S494P) had similar affinity and two (K417N and E484K) had weaker affinity than the wildtype. Compared with the wildtype, four mutants (K417N, Y453F, N501Y, and K417T/E484K/N501Y) had weaker affinity for the CC12.1 antibody, whereas two (S477N and S494P) had similar affinity, and two (T478I and E484K) had stronger affinity than the wildtype. Mutants also differ in their thermal stability, with the two least stable mutants showing reduced expression. Taken together, these results indicate that multiple factors contribute toward the natural selection of variants, and all these factors need to be considered to understand the evolution of the virus. In addition, since not all variants can escape a given neutralizing antibody, antibodies to treat new variants can be chosen based on the specific mutations in that variant.

Keywords

protein stability
protein binding
protein function
protein structure
protein expression
COVID-19
SARS-CoV-2
ACE2
antibodies
variants

Abbreviations

ACE2
angiotensin-converting enzyme 2
COVID-19
coronavirus disease 2019
ER
endoplasmic reticulum
HEK
human embryonic kidney
ITC
isothermal titration calorimetry
PDB
Protein Data Bank
RBD
receptor-binding domain
RBM
receptor-binding motif
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
ScFv
single-chain fragment variable
VOC
variant of concern

Cited by (0)

Present address for Ryuki Miyauchi: Modality Research Laboratories, Daiichi-Sankyo Co, Ltd, Tokyo 134-8630, Japan.